## Abstract The extent to which HIV‐1 proviral DNA mutations cause clinically relevant antiretroviral resistance is still controversial. Paired plasma HIV‐1 RNA and whole blood DNA were compared in patients failing HAART to investigate if the additional knowledge of archived mutations could improve
Prevalence of mutations related to HIV-1 antiretroviral resistance in Brazilian patients failing HAART
✍ Scribed by Amilcar Tanuri; Elena Caridea; Maria C. Dantas; Marisa G. Morgado; Daise L.C. Mello; Sandra Borges; Marisa Tavares; Selma B. Ferreira; Guilherme Santoro-Lopes; Claudia R.F. Martins; André L.C. Esteves; Ricardo S. Diaz; Sandra M.S. Andreo; Luiz A.P. Ferreira; Rodrigo Rodrigues; Tania Reuter; Ana M.S. Cavalcanti; Suelene M. de Oliveira; Heraclito B. de Barbosa; Paulo R. Teixeira; Pedro N. Chequer
- Book ID
- 117769513
- Publisher
- Elsevier Science
- Year
- 2002
- Tongue
- English
- Weight
- 121 KB
- Volume
- 25
- Category
- Article
- ISSN
- 1386-6532
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
The emergence of mutations encoding drug resistance is supposed to be a significant limitation to the clinical efficacy of inhibitor compounds directed against specific HIV-1 enzymatic targets. We have used a commercial test (Visible Genetics Inc., Paris, France) to study the prevalence of mutations
## Abstract The aim of the study was to describe the pattern of resistance mutations in human immunodeficiency virus type 1 (HIV‐1) infected patients experiencing their first protease inhibitor (PI) failure on nelfinavir (NFV)‐containing therapy. Earlier PI‐naïve patients (n = 172) with NFV‐contain